Authors
Latest:
Microbiome Analysis and Probiotics for the Prevention and Treatment of Food Allergy and Atopic DermatitisResearchers are investigating whether microbial therapy can be an effective treatment for several skin and allergic conditions.
Latest:
New Uterine Fibroids Oral Treatment Could Replace Surgery (UPDATE)A potential first-in-class, oral medication to treat uterine fibroids has been accepted by the FDA.
Latest:
Tafamidis Gets Breakthrough Therapy DesignationThis morning, Pfizer announced that its investigational therapy for the treatment of patients with transthyretin (TTR) cardiomyopathy, tafamidis, received Breakthrough Therapy designation from the US FDA.
Latest:
Letermovir Important Regimen for CMV PreventionThe indication for letermovir represents a significant milestone, since CMV infection remains the most common complication of stem cell transplantation for patients with cancer.
Latest:
Anthracyclines and Trastuzumab Bests Taxane/Carboplatin/TrastuzumabAnthracycline chemotherapy plus trastuzumab outperformed anthracycline alone, and performed similarly to a non-anthracycline regimen in breast cancer patients.
Latest:
Benefits of Using CART-T Therapies to Treat Rare CancersManuel Litchman, MD, President and CEO of Mustang Bio Inc, highlights the advantages of using CAR-T therapies as treatments for rare cancers.
Latest:
The SORT OUT II trial: Updated summary with a special focus on stent thrombosis and discontinuation of dual antiplatelet therapy after 1 yearThe SORT OUT II trial showed that the first generation of drug-eluting stents, Cypher® and Taxus®, exhibit similar efficacy and safety when used for percutaneous coronary intervention in everyday practice, including in a high proportion of off-label situations.
Latest:
Elevated high-density lipoprotein cholesterol and carotid atherosclerosisWe assessed the relationship between high-density lipoprotein (HDL) cholesterol level and carotid plaque progression in 1952 men and women with preexisting carotid atherosclerosis over a period of 7 years. The HDL cholesterol level was inversely related to plaque growth. The plaques that became more echogenic during follow-up had a lower growth rate compared with those that became more echolucent. These findings suggest that HDL cholesterol stabilizes plaques and counteracts their growth by reducing their lipid content and inflammation.
Latest:
Cholesterol-lowering therapies and C-reactive proteinLow-density lipoprotein (LDL) cholesterol-lowering therapy decreases C-reactive protein (CRP) levels, but the importance of LDL cholesterol-independent effects is uncertain because of the variability in measuring LDL cholesterol and CRP levels in any individual patient. In this study, this variability was reduced by comparing average changes in LDL cholesterol and CRP levels after treatment with lipid-lowering therapy across different studies.
Latest:
Reduction of inflammatory biomarkers through the use of hyperlipidemia drugs in patients with diabetesDiabetes and inflammation influence the development of atherosclerosis. We performed a study that showed the inflammatory markers high-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 were lowered with the use of fenofibrate, simvastatin, and combination therapy. The anti-inflammatory effects were most pronounced among patients with elevated baseline inflammatory markers. Combination therapy significantly altered lipid concentrations and exerted a greater positive effect on low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides than monotherapy with either drug.
Latest:
Cannabidiol Produces Dose-Dependent Seizure Control in Adults and ChildrenHighly-purified cannabidiol (CBD) marketed as Epidiolex can lower the chances of seizures in adults and children with epilepsy.
Latest:
NIH Launches Hydroxychloroquine Trial to Evaluate Efficacy for COVID-19The blinded, placebo-controlled randomized clinical trial will seek to enroll more than 500 adult patients.
